Updated on 2025/04/20

写真a

 
Kitamura Wataru
 
Organization
Scheduled update Special-Appointment Assistant Professor
Position
Special-Appointment Assistant Professor
External link

Research Interests

  • 自律神経

  • 造血幹細胞ニッチ

Research Areas

  • Life Science / Hematology and medical oncology

Education

  • Jichi Medical University   医学部   医学科

    2005.4 - 2011.3

      More details

    Country: Japan

    researchmap

  • Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences   Department of Hematology, Oncology and Respiratory Medicine  

    2021.4

      More details

    Country: Japan

    researchmap

Research History

  • 岡山大学病院   助教

    2025.4

      More details

  • 岡山大学病院   医員

    2024.4 - 2025.3

      More details

  • 岡山大学病院   研究助教

    2024.4 - 2025.3

      More details

  • 独立行政法人国立病院機構 岩国医療センター   非常勤医

    2021.4 - 2024.3

      More details

  • 岡山大学病院   医員

    2020.4 - 2021.3

      More details

▼display all

Professional Memberships

 

Papers

  • Markedly elevated serum level of presepsin in agranulocytosis with hematologic malignancy: A potential prognostic factor in a single-institution retrospective study after granulocyte transfusion Reviewed

    Takuya Fukumi, Keiko Fujii, Wataru Kitamura, Kazuhiro Ikeuchi, Naomi Asano, Akira Yamamoto, Hiroki Kobayashi, Takumi Kondo, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Ken-ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda, Nobuharu Fujii

    Laboratory Medicine   2025.3

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/labmed/lmae118

    researchmap

  • COMFORT OF APHERESIS: USE OF THE INTERMITTENT AIR COMPRESSION METHODANDITSEFFECTS Reviewed

    Naoe Takagi, Keiko Fujii, Yachiyo Masuda, Ayumi Okada, Kazuhiro Ikeuchi, Wataru Kitamura, Nobuharu Fujii

    日本輸血細胞治療学会誌   71 ( 1 )   9 - 16   2025.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.3925/jjtc.71.9

    researchmap

  • A randomized controlled trial of conventional GVHD prophylaxis with or without teprenone for the prevention of severe acute GVHD Reviewed

    Wataru Kitamura, Keiko Fujii, Mitsuru Tsuge, Toshiharu Mitsuhashi, Hiroki Kobayashi, Chihiro Kamoi, Akira Yamamoto, Takumi Kondo, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Ken-ichi Matsuoka, Nobuharu Fujii, Yoshinobu Maeda

    Annals of Hematology   2025.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    <jats:title>Abstract</jats:title>
    <jats:p>Therapies that effectively suppress graft-versus-host disease (GVHD) without compromising graft-versus-leukemia/lymphoma (GVL) effects is important in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematopoietic malignancies. Geranylgeranylacetone (GGA) is a main component of teprenone, a gastric mucosal protectant commonly used in clinical practice. In preclinical models, GGA suppresses proinflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α), which are associated with GVHD as well as induces thioredoxin-1 (Trx-1), which suppresses GVHD while maintaining GVL effects. Here, we investigated whether the addition of teprenone to standard GVHD prophylaxis could reduce the cumulative incidence of severe acute GVHD (aGVHD) without attenuating GVL effects. This open-label, randomized clinical trial enrolled 40 patients (21 control and 19 teprenone group) who received allo-HSCT between May 2022 and February 2023 in our institution. Patients in the teprenone group received 50 mg of teprenone orally thrice daily for 21 days from the initiation of the conditioning regimen. The cumulative incidence of severe aGVHD by day 100 after allo-HSCT was not significantly different in the two groups (27.9 vs. 16.1%, <jats:italic>p</jats:italic> = 0.25). The exploratory studies revealed no obvious changes in Trx-1 levels, but the alternations from baseline in IL-1β and TNF-α levels at day 28 after allo-HSCT tended to be lower in the teprenone group. In conclusion, we could not demonstrate that teprenone significantly prevented the development of severe aGVHD. Discrepancy with preclinical model suggests that appropriate dose of teprenone may be necessary to induce the expression of antioxidant enzymes that suppress severe aGVHD. Clinical Trial Registration number:jRCTs 061210072.</jats:p>

    DOI: 10.1007/s00277-025-06269-2

    researchmap

  • Myelodysplastic neoplasms with repeating TAFRO syndrome-like symptoms Reviewed

    Kenta Hayashino, Nobuharu Fujii, Tomohiro Nagano, Daisuke Ikeda, Kanako Fujiwara, Risa Hashida, Wataru Kitamura, Hiroki Kobayashi, Takumi Kondo, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Keiko Fujii, Ken-ichi Matsuoka, Yoshinobu Maeda

    International Journal of Hematology   2025.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-025-03937-x

    researchmap

  • [Treatment outcomes of axicabtagene ciloleucel for relapsed/refractory diffuse large B-cell lymphoma: a retrospective analysis at a single institution]. Reviewed

    Wataru Kitamura, Nobuharu Fujii, Chihiro Kamoi, Toshiki Terao, Akira Yamamoto, Hiroki Kobayashi, Takumi Kondo, Keisuke Seike, Hideaki Fujiwara, Keiko Fujii, Noboru Asada, Daisuke Ennishi, Yoshinobu Maeda

    [Rinsho ketsueki] The Japanese journal of clinical hematology   66 ( 2 )   81 - 91   2025.2

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

    The advent of anti-CD19 chimeric antigen receptor-T cell therapy has dramatically changed the treatment strategy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Three products are recently available in Japan, but to the best of our knowledge, real-world data are only available for tisagenlecleucel. This study was a retrospective analysis of 27 patients who received axicabtagene ciloleucel (axi-cel) for R/R DLBCL at our institution. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in 24 (88.9%) and 8 patients (29.6%), respectively, and corticosteroids were used in 19 patients (70.4%). The median follow-up period was 8.1 months (range, 1.0-23.2), and the 6-month progression-free survival and overall survival rates were 80.2% (95% confidence interval [CI], 58.8-91.3) and 92.0% (95%CI, 71.6-97.9), respectively. Although our study was limited by its small sample size and short follow-up period, it demonstrated that axi-cel was highly effective and safe at our institution.

    DOI: 10.11406/rinketsu.66.81

    PubMed

    researchmap

▼display all

Presentations

  • 当院における再発・難治性DLBCLに対する3種類の抗CD19 CAR T製剤の治療成績

    鴨井 千尋, 北村 亘, 藤井 伸治, 寺尾 俊紀, 池内 一廣, 小林 宏紀, 近藤 匠, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 藤井 敬子, 前田 嘉信

    第47回 日本造血・免疫細胞療法学会総会  2025.2.28 

     More details

  • Alpha 2-Adrenergic Agonist As a Novel Microenvironment-Directed Agent for Acute Myeloid Leukemia via Notch Signaling Inhibition

    Wataru Kitamura, Masakazu Shinohara, Akifumi Matsumura, Takashi Moriyama, Masaya Abe, Yayoi Ueda, Shin-ichi Ishii, Tomohide Suzuki, Mitsuaki Ono, Yoshinobu Maeda, Noboru Asada

    66th ASH Annual Meeting  2024.12.7 

     More details

  • 当院における再発難治性びまん性大細胞型B細胞性リンパ腫に対するtisagenlecleucelの治療成績

    北村 亘, 藤井 伸治, 鴨井 千尋, 阿部 将也, 住居 優一, 浦田 知宏, 谷 勝真, 高木 尚江, 山本 晃, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    第71回 日本輸血・細胞治療学会学術総会  2023.5.12 

     More details

  • Prolonged Cytopenia after CAR-T Cell Therapy Is Associated with BM Niche Disruption and a Sustained Inflammation in the BM

    Wataru Kitamura, Noboru Asada, Yusuke Naoi, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    2023 Tandem meeting/Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR  2023.2.15 

     More details

  • PTCY-haploを施行した骨髄系腫瘍患者におけるDay +30 WT1の予後への影響: OHSGによる多施設共同研究

    北村 亘, 藤井 伸治, 名和 由一郎, 杉浦 弘幸, 藤下 惠悟, 吉岡 尚徳, 藤原 悠紀, 大山 矩史, 村上 裕之, 高須賀 裕樹, 池内 一廣, 池川 俊太郎, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 木口 亨, 今井 利, 平松 靖史, 前田 嘉信

    第83回 日本血液学会学術集会  2021.9.24 

     More details

▼display all

Awards

  • 岡山県医師会学術奨励賞

    2024.12   岡山県医師会  

     More details

Research Projects

  • Exploring regulation of extramedullary hematopoiesis targeting neuropeptide

    Grant number:24K23413  2024.07 - 2026.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Research Activity Start-up

    北村 亘

      More details

    Grant amount:\2730000 ( Direct expense: \2100000 、 Indirect expense:\630000 )

    researchmap